Dr. Mailankody on BCMA CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS
Published: Wednesday, Dec 04, 2019



Sham Mailankody, MBBS, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.

There are many studies examining BCMA CAR T-cell therapy in various stages of clinical development. A recent publication in the New England Journal of Medicine showed that bb2121, a BCMA CAR T-cell product that was used for treatment of patients with relapsed/refractory multiple myeloma, is associated with high response rates, explains Mailankody.

The overall response rate was 85% and the complete response rate was 45%, which is unprecedented in this patient population. However, relapses are common and, in this study, the median progression-free survival was 11.7 months, showing that there is room for improvement, Mailankody concludes.
SELECTED
LANGUAGE


Sham Mailankody, MBBS, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.

There are many studies examining BCMA CAR T-cell therapy in various stages of clinical development. A recent publication in the New England Journal of Medicine showed that bb2121, a BCMA CAR T-cell product that was used for treatment of patients with relapsed/refractory multiple myeloma, is associated with high response rates, explains Mailankody.

The overall response rate was 85% and the complete response rate was 45%, which is unprecedented in this patient population. However, relapses are common and, in this study, the median progression-free survival was 11.7 months, showing that there is room for improvement, Mailankody concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x